Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith D Eaton

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
NPJ Precision Oncology|March 20, 2025
Revealing neuroendocrine transformation in gynecological cancers through genomic analysisAnn Oluloro, David L Wells, Charles K Childers, et al.
Cancer Treatment and Research Communications|November 1, 2025
Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancerKevin M Levine, Natalie F Uy, Ted A Gooley, et al.
BMC Cancer|October 5, 2012
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancerJulie E Bauman, Keith D Eaton, Sarah G Wallace, et al.
Plos One|June 14, 2013
Plasma processing conditions substantially influence circulating microRNA biomarker levelsHeather H Cheng, Hye Son Yi, Yeonju Kim, et al.
Investigational New Drugs|January 16, 2018
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumorsGentry T King, Keith D Eaton, Brandon R Beagle, et al.
American Journal of Clinical Pathology|July 18, 2015
Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric PatientsMin Fang, Pamela S Becker, Michael Linenberger, et al.
Journal of Oncology Practice|February 18, 2018
Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional StudyLaura Panattoni, Catherine Fedorenko, Mikael Anne Greenwood-Hickman, et al.
The Laryngoscope|December 2, 2016
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinomaBruna Pellini Ferreira, Mary Redman, Kelsey K Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2016
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerSai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, et al.
Oral Oncology|November 21, 2021
Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institutionPerrin E Romine, Jenna Voutsinas, Vicky Wu, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
NPJ Precision Oncology|March 20, 2025
Revealing neuroendocrine transformation in gynecological cancers through genomic analysisAnn Oluloro, David L Wells, Charles K Childers, et al.
Cancer Treatment and Research Communications|November 1, 2025
Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancerKevin M Levine, Natalie F Uy, Ted A Gooley, et al.
BMC Cancer|October 5, 2012
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancerJulie E Bauman, Keith D Eaton, Sarah G Wallace, et al.
Plos One|June 14, 2013
Plasma processing conditions substantially influence circulating microRNA biomarker levelsHeather H Cheng, Hye Son Yi, Yeonju Kim, et al.
Investigational New Drugs|January 16, 2018
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumorsGentry T King, Keith D Eaton, Brandon R Beagle, et al.
American Journal of Clinical Pathology|July 18, 2015
Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric PatientsMin Fang, Pamela S Becker, Michael Linenberger, et al.
Journal of Oncology Practice|February 18, 2018
Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional StudyLaura Panattoni, Catherine Fedorenko, Mikael Anne Greenwood-Hickman, et al.
The Laryngoscope|December 2, 2016
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinomaBruna Pellini Ferreira, Mary Redman, Kelsey K Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2016
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerSai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, et al.
Oral Oncology|November 21, 2021
Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institutionPerrin E Romine, Jenna Voutsinas, Vicky Wu, et al.
Pageof 6